[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! View ALL results for your Stocks, ETFs and Funds Screeners with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Verastem Inc (VSTM)

Verastem Inc (VSTM)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 362,041
  • Shares Outstanding, K 87,874
  • Annual Sales, $ 30,910 K
  • Annual Income, $ -209,470 K
  • EBIT $ -171 M
  • EBITDA $ -170 M
  • 60-Month Beta 0.27
  • Price/Sales 11.85
  • Price/Cash Flow N/A
  • Price/Book 4.43

Options Overview Details

View History
  • Implied Volatility 153.11% (-184.68%)
  • Historical Volatility 71.38%
  • IV Percentile 23%
  • IV Rank 10.87%
  • IV High 755.94% on 03/03/26
  • IV Low 79.60% on 05/18/26
  • Expected Move (DTE 26) 0.51 (12.38%)
  • Put/Call Vol Ratio 0.27
  • Today's Volume 750
  • Volume Avg (30-Day) 473
  • Put/Call OI Ratio 0.13
  • Today's Open Interest 22,648
  • Open Int (30-Day) 20,895
  • Expected Range 3.61 to 4.63

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 9 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/26
See More
  • Average Estimate $-0.45
  • Number of Estimates 2
  • High Estimate $-0.45
  • Low Estimate $-0.45
  • Prior Year $-0.39
  • Growth Rate Est. (year over year) -15.38%

Price Performance

See More
Period Period Low Period High Performance
1-Month
3.55 +16.06%
on 06/09/26
4.53 -9.05%
on 05/27/26
-0.14 (-3.29%)
since 05/18/26
3-Month
3.55 +16.06%
on 06/09/26
6.80 -39.37%
on 04/17/26
-1.44 (-25.90%)
since 03/18/26
52-Week
3.55 +16.06%
on 06/09/26
11.24 -63.36%
on 09/05/25
-1.07 (-20.62%)
since 06/18/25

Most Recent Stories

More News
Verastem Oncology Announces Positive Updated Results from RAMP 205 Evaluating Avutometinib Plus Defactinib in Combination with Standard-of-Care Chemotherapy in First-Line Metastatic Pancreatic Cancer

90% of patients in the study presented with metastatic (Stage IV) disease at diagnosis 6-month overall survival rate was 86%; follow-up continues and survival data continue...

VSTM : 4.12 (-1.20%)
Verastem Oncology Doses First Patient in TARGET-D 201 Phase 2 Registration-Directed Trial of VS-7375 Oral KRAS G12D (ON/OFF) Inhibitor for KRAS G12D-Mutated Metastatic Pancreatic Cancer

TARGET-D 201 trial to evaluate VS-7375 both as monotherapy and in combination with cetuximab for second-line treatment of metastatic pancreatic cancer A cohort in TARGET-D...

VSTM : 4.12 (-1.20%)
Verastem Oncology to Host Investor Conference Call and Report Updated Data and Progress Across VS-7375 Oral KRAS G12D (ON/OFF) Inhibitor TARGET-D Clinical Program

Featuring updated preliminary clinical data across tumor types from the Phase 1/2 TARGET-D 101 trial Company to host investor conference call and webcast on Tuesday, June...

VSTM : 4.12 (-1.20%)
Verastem Oncology Announces U.S. FDA Fast Track Designation for VS-7375, an Oral and Potential Best-in-Class Investigational KRAS G12D (ON/OFF) Inhibitor for the Treatment of KRAS G12D-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer

Phase 1 TARGET-D 101 dose escalation, dose expansion, and combination clinical trial ongoing with early data updates expected in the first half of 2026 and more mature data expected in the second half...

VSTM : 4.12 (-1.20%)
Verastem Oncology to Present at Jefferies Healthcare Conference

Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced that its management team is scheduled...

VSTM : 4.12 (-1.20%)
Verastem Oncology Appoints Michael P. Bailey to its Board of Directors

Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced the appointment of Michael...

VSTM : 4.12 (-1.20%)
Verastem Oncology to Present at Upcoming Investor Conferences

Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced that its management team is scheduled...

VSTM : 4.12 (-1.20%)
Verastem Q1 Earnings Call Highlights

Verastem (NASDAQ:VSTM) reported first-quarter 2026 net product revenue of $18.7 million for AVMAPKI FAKZYNJA CO-PACK, as management said the launch of the therapy for KRAS-mutated recurrent low-grade serous...

VSTM : 4.12 (-1.20%)
On World Ovarian Cancer Day, LGSOC Resource Guide Launches to Support People Living with Low-Grade Serous Ovarian Cancer

Available at LGSOCAwarenessDay.Org, the LGSOC Resource Guide brings together resources from patient advocacy groups, covering topics from diagnosis to survivorship

VSTM : 4.12 (-1.20%)
Verastem: Q1 Earnings Snapshot

Verastem: Q1 Earnings Snapshot

VSTM : 4.12 (-1.20%)

Business Summary

Verastem, Inc., a clinical stage biopharmaceutical company, focuses on discovering and developing drugs to improve outcomes for patients with cancer. Its programs target the focal adhesion kinase (FAK) and the phosphoinositide 3-kinase (PI3K)/mTOR signaling pathways. Its lead FAK inhibitor is defactinib...

See More

Key Turning Points

3rd Resistance Point 4.64
2nd Resistance Point 4.53
1st Resistance Point 4.33
Last Price 4.12
1st Support Level 4.01
2nd Support Level 3.90
3rd Support Level 3.70

See More

52-Week High 11.24
Fibonacci 61.8% 8.31
Fibonacci 50% 7.40
Fibonacci 38.2% 6.49
Last Price 4.12
52-Week Low 3.55

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.